S&P 500   4,579.37 (-1.63%)
DOW   34,527.77 (-1.73%)
QQQ   393.33 (-1.59%)
AAPL   163.23 (+1.87%)
MSFT   330.37 (-1.86%)
FB   327.70 (-3.06%)
GOOGL   2,858.28 (-1.80%)
AMZN   3,508.25 (-1.50%)
TSLA   1,132.28 (-0.41%)
NVDA   321.71 (-3.61%)
BABA   126.69 (-3.74%)
NIO   38.79 (-4.13%)
CGC   10.40 (-5.97%)
AMD   157.14 (-2.95%)
GE   95.19 (-3.26%)
MU   84.90 (-1.44%)
T   22.69 (-5.02%)
F   19.25 (-2.14%)
DIS   143.83 (-2.69%)
ACB   6.17 (-4.19%)
AMC   33.76 (-8.36%)
PFE   53.88 (+2.82%)
BA   194.78 (-1.87%)
S&P 500   4,579.37 (-1.63%)
DOW   34,527.77 (-1.73%)
QQQ   393.33 (-1.59%)
AAPL   163.23 (+1.87%)
MSFT   330.37 (-1.86%)
FB   327.70 (-3.06%)
GOOGL   2,858.28 (-1.80%)
AMZN   3,508.25 (-1.50%)
TSLA   1,132.28 (-0.41%)
NVDA   321.71 (-3.61%)
BABA   126.69 (-3.74%)
NIO   38.79 (-4.13%)
CGC   10.40 (-5.97%)
AMD   157.14 (-2.95%)
GE   95.19 (-3.26%)
MU   84.90 (-1.44%)
T   22.69 (-5.02%)
F   19.25 (-2.14%)
DIS   143.83 (-2.69%)
ACB   6.17 (-4.19%)
AMC   33.76 (-8.36%)
PFE   53.88 (+2.82%)
BA   194.78 (-1.87%)
S&P 500   4,579.37 (-1.63%)
DOW   34,527.77 (-1.73%)
QQQ   393.33 (-1.59%)
AAPL   163.23 (+1.87%)
MSFT   330.37 (-1.86%)
FB   327.70 (-3.06%)
GOOGL   2,858.28 (-1.80%)
AMZN   3,508.25 (-1.50%)
TSLA   1,132.28 (-0.41%)
NVDA   321.71 (-3.61%)
BABA   126.69 (-3.74%)
NIO   38.79 (-4.13%)
CGC   10.40 (-5.97%)
AMD   157.14 (-2.95%)
GE   95.19 (-3.26%)
MU   84.90 (-1.44%)
T   22.69 (-5.02%)
F   19.25 (-2.14%)
DIS   143.83 (-2.69%)
ACB   6.17 (-4.19%)
AMC   33.76 (-8.36%)
PFE   53.88 (+2.82%)
BA   194.78 (-1.87%)
S&P 500   4,579.37 (-1.63%)
DOW   34,527.77 (-1.73%)
QQQ   393.33 (-1.59%)
AAPL   163.23 (+1.87%)
MSFT   330.37 (-1.86%)
FB   327.70 (-3.06%)
GOOGL   2,858.28 (-1.80%)
AMZN   3,508.25 (-1.50%)
TSLA   1,132.28 (-0.41%)
NVDA   321.71 (-3.61%)
BABA   126.69 (-3.74%)
NIO   38.79 (-4.13%)
CGC   10.40 (-5.97%)
AMD   157.14 (-2.95%)
GE   95.19 (-3.26%)
MU   84.90 (-1.44%)
T   22.69 (-5.02%)
F   19.25 (-2.14%)
DIS   143.83 (-2.69%)
ACB   6.17 (-4.19%)
AMC   33.76 (-8.36%)
PFE   53.88 (+2.82%)
BA   194.78 (-1.87%)
NASDAQ:TRDA

Entrada Therapeutics Stock Forecast, Price & News

$28.78
-1.52 (-5.02%)
(As of 11/30/2021 12:27 PM ET)
Add
Compare
Today's Range
$28.01
$31.63
50-Day Range
N/A
52-Week Range
$20.00
$36.85
Volume
3,645 shs
Average Volume
225,394 shs
Market Capitalization
$860.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive TRDA News and Ratings via Email

Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Entrada Therapeutics

Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.

Headlines

Entrada Therapeutics (NASDAQ:TRDA) Coverage Initiated at Evercore ISI
November 24, 2021 |  americanbankingnews.com
Entrada Therapeutics (NASDAQ:TRDA) Now Covered by Cowen
November 23, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRDA
Web
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$860.15 million
Optionable
Not Optionable

Company Calendar

Today
11/30/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.15 out of 5 stars

Medical Sector

1210th out of 1,390 stocks

Analyst Opinion: 1.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Entrada Therapeutics (NASDAQ:TRDA) Frequently Asked Questions

Is Entrada Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Entrada Therapeutics stock.
View analyst ratings for Entrada Therapeutics
or view top-rated stocks.

What price target have analysts set for TRDA?

3 analysts have issued 12-month price objectives for Entrada Therapeutics' shares. Their forecasts range from $29.00 to $29.00. On average, they anticipate Entrada Therapeutics' share price to reach $29.00 in the next year. This suggests a possible upside of 0.8% from the stock's current price.
View analysts' price targets for Entrada Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Entrada Therapeutics IPO?

(TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share.

What is Entrada Therapeutics' stock symbol?

Entrada Therapeutics trades on the NASDAQ under the ticker symbol "TRDA."

When does the company's quiet period expire?

Entrada Therapeutics' quiet period expires on Wednesday, December 8th. Entrada Therapeutics had issued 9,075,000 shares in its IPO on October 29th. The total size of the offering was $181,500,000 based on an initial share price of $20.00. During the company's quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Entrada Therapeutics?

Shares of TRDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entrada Therapeutics' stock price today?

One share of TRDA stock can currently be purchased for approximately $28.78.

How much money does Entrada Therapeutics make?

Entrada Therapeutics has a market capitalization of $860.15 million.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.